SEHK:1801Biotechs
Innovent Biologics (SEHK:1801) Is Up 9.1% After Striking US$1.10 Billion IBI355 Licensing Deal
Innovent Biologics recently announced an exclusive license agreement granting Spero Therapeutics rights to develop and commercialize IBI355 outside Greater China, with Innovent eligible for up to approximately US$1.10 billion in upfront and milestone payments plus tiered royalties.
The arrangement effectively turns IBI355 into a globally partnered asset, allowing Innovent to keep Greater China rights while leveraging Spero’s international development plans in IgG4-related disease and...